This page has been archived on the Web
Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.
Slimming Factor
- Starting date:
- February 3, 2011
- Posting date:
- February 3, 2011
- Type of communication:
- Foreign Product Alert (FPA)
- Subcategory:
- Natural health products
- Source of recall:
- Health Canada
- Issue:
- Undeclared Substance, Product Safety
- Audience:
- General Public
- Identification number:
- RA-120001635
These products are not authorized for sale in Canada and have not been found in the Canadian marketplace, but it is possible they may have been brought into the country by travellers or purchased over the Internet.
Source of alert
Australia Therapeutic Goods Administration (TGA)
Product names
Slimming Factor
Manufacturer / Place of origin
Unknown
Product description
Slimming Factor is promoted as a 100% herbal product used for weight loss. The product contains two different-coloured capsules.
Reason for warning
The Australian TGA warned consumers not to buy or use Slimming Factor after TGA lab tests confirmed the presence of the undeclared substances sibutramine, fenfluramine and phenolphthalein. According to the TGA release, the product is sold over the Internet.
Sibutramine was previously used to treat obesity but is no longer authorized for sale in Canada because of its association with an increased risk of cardiovascular side effects such as heart attack and stroke.
Fenfluramine was previously used to treat obesity but is no longer authorized for sale in Canada because of its association with primary pulmonary hypertension (severe lung disease) and heart valve disease.
Phenolphthalein was previously used as a laxative but is no longer authorized for sale in Canada because it may cause cancer.
Possible side effects
In addition to heart attack and stroke, side effects associated with sibutramine include increased blood pressure and heart rate, dry mouth, difficulty sleeping and constipation.
Additional side effects associated with fenfluramine include headache, drowsiness, dizziness, palpitation, diarrhea and dry mouth.
Additional side effects associated with phenolphthalein include decreased blood pressure, skin rash and gastrointestinal bleeding.
What you should do
Canadians who have this product are advised not to use it, and should consult with a health care professional if they have concerns about their health related to the use of this product.
Health Canada advises Canadians to contact the Health Products and Food Branch Inspectorate at 1-800-267-9675 if they find the product listed above in the Canadian marketplace.
Background
Drugs and natural health products that are authorized for sale in Canada will have either an eight-digit Drug Identification Number (DIN), a Natural Product Number (NPN) or a Homeopathic Medicine Number (DIN-HM) on the label. These numbers indicate that the products have been assessed by Health Canada for safety, effectiveness and quality.
As of the date of this posting, no adverse reactions suspected to be associated with the use of this product have been reported in Canada.
Report a health or safety concern
- Call toll-free at 1-866-234-2345.
- Visit Health Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.
Media enquiries
Health Canada
613-957-2983
Public enquiries
613-957-2991
1-866-225-0709
Images
Select thumbnail to enlarge - opens in a new window